Provided herein are transdermal delivery devices comprising dextromethorphan. The transdermal delivery device can be characterized by the novel design, for example, with an adhesive layer and a reservoir layer, with an adhesive layer comprising a mixture of two adhesives, and/or with a skin permeation enhancer, e.g., in an amount that can significantly enhance the flux of dextromethorphan. The transdermal delivery device can also be characterized by its in vitro and/or in vivo release profile, for example, that can provide a desired pharmacokinetic profile described herein. Also provided herein are methods of administering dextromethorphan, and methods of treating a disease or disorder described herein, using the transdermal delivery device herein.

The present invention provides a pharmaceutical composition containing the following compound having antiviral action:

##STR00001##

P is hydrogen or a group to form a prodrug;
A.sup.1 is CR.sup.1AR.sup.1B, S or O;
A.sup.2 is CR.sup.2AR.sup.2B, S or O;
A.sup.3 is CR.sup.3AR.sup.3B, S or O;
A.sup.4 is each independently CR.sup.4AR.sup.4B, S or O;
the number of hetero atoms among atoms constituting the ring which consists of A.sup.1, A.sup.2, A.sup.3, A.sup.4, nitrogen atom adjacent to A.sup.1 and carbon atom adjacent to A.sup.4, is 1 or 2;
R.sup.1A and R.sup.1B are each independently hydrogen, halogen, alkyl, or the like;
R.sup.2A and R.sup.2B are each independently hydrogen, halogen, alkyl, or the like;
R.sup.3A and R.sup.3B are each independently hydrogen, halogen, alkyl, or the like;
R.sup.4A and R.sup.4B are each independently hydrogen, halogen, alkyl, or the like;
R.sup.3A and R.sup.3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle;
R.sup.1 is fluorine;
m is any integer of 1 to 2; and
n is any integer of 1 to 2.

The present invention provides a packaging material for a patch, the packaging material comprising: an inner layer film made of a polyethylene terephthalate-based resin having heat sealing properties; and a substrate film, wherein a heat-sealing surface of the inner layer film comprises an isophthalic acid-modified polyethylene terephthalate resin having a copolymerization ratio of isophthalic acid component of 10 mol % to 20 mol %. More preferably, the inner layer film made of the polyethylene terephthalate-based resin having heat sealing properties is a multi-layer film comprising at least two layers including a heat sealing surface side layer made of an isophthalic acid-modified polyethylene terephthalate resin having a copolymerization ratio of isophthalic acid component of 10 mol % to 20 mol % and a layer made of an isophthalic acid-modified polyethylene terephthalate resin having a copolymerization ratio of isophthalic acid component of 0 mol % to 5 mol %.

Methods, compositions, and devices for enhancing transdermal delivery of large agents.

Provided herein are transdermal delivery devices comprising dextromethorphan. The transdermal delivery device can be characterized by the novel design, for example, with an adhesive layer and a reservoir layer, with an adhesive layer comprising a mixture of two adhesives, and/or with a skin permeation enhancer, e.g., in an amount that can significantly enhance the flux of dextromethorphan. The transdermal delivery device can also be characterized by its in vitro and/or in vivo release profile, for example, that can provide a desired pharmacokinetic profile described herein. Also provided herein are methods of administering dextromethorphan, and methods of treating a disease or disorder described herein, using the transdermal delivery device herein.

The present invention provides a gel patch having a paste layer on a support, wherein the paste layer comprising ketoprofen or a pharmaceutically acceptable salt thereof, propylene glycol, 1-menthol, and water, wherein the mass of propylene glycol in the paste layer is 3-fold the mass of ketoprofen or less, and wherein the content of 1-menthol based on a total mass of the paste layer is 0.1 to 0.5 mass %.

A product includes a metallogel material having metal ions dispersed in an assembly having an organic compound. A method includes combining a metal salt, an organic compound precursor, and a glyme for forming a metallogel material having metal ions dispersed in an assembly having an organic compound.

A method for suppressing a plasma concentration of an asenapine metabolite includes applying to a subject a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer includes asenapine and/or a pharmaceutically acceptable salt thereof, and an adhesive base agent.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

The present disclosure relates to the transdermal administration of psychedelics, such as psilocybin, psilocin, lysergic acid diethylamine (LSD), and/or ibogaine, and derivatives of these compounds, for the treatment and/or prevention and/or control of severe depression (treatment resistant), major depressive disorder, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, opioid addiction, anxiety (stress), adult ADHD, cluster headaches, and cancer related or other end-of-life psychological distress.